| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 11.05.
| Threshold Pharmaceutical's TH-302 Could Be A Blockbuster By Targeting Hypoxia In Cancer | | 5 | Seeking Alpha |
| 03.05.
| THRESHOLD PHARMACEUTICALS INC - 10-Q, Quarterly Report | | 1 | SEC Filings |
| 03.05.
| Threshold Pharmaceuticals Reports First Quarter 2012 Financial and Operational Results | | 27 | MarketWire |
| SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 05/03/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today reported financial results for the first quarter ended March 31, 2012. Revenue for the first...
Mehr lesen zu:
Threshold Pharmaceuticals Reports First Quarter 2012 Financial and Operational Results | |
| 25.04.
| Threshold Pharmaceuticals Appoints Robert Simon as Senior Vice President of Regulatory Affairs | | 20 | MarketWire |
| SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/25/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the appointment of Robert Simon as Senior Vice President of Regulatory Affairs....
Mehr lesen zu:
Threshold Pharmaceuticals Appoints Robert Simon as Senior Vice President of Regulatory Affairs | |
| 17.04.
| Notable Options Activity in Threshold Pharmaceuticals | | 4 | Benzinga.com |
| 13.04.
| Threshold Pharmaceuticals Announces Presentation and Webcast at BioCentury Future Leaders Conference | | 36 | MarketWire |
| SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/13/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Chief Executive Officer of Threshold, is scheduled to present...
Mehr lesen zu:
Threshold Pharmaceuticals Announces Presentation and Webcast at BioCentury Future Leaders Conference | |
| 11.04.
| Threshold Pharmaceuticals Receives $20 Million Milestone Payment | | 2 | SmarTrend |
| 11.04.
| Threshold Pharmaceuticals Earns $20 Million Milestone Payment | | - | Benzinga.com |
| 11.04.
| Threshold Pharmaceuticals Earns $20 Million Milestone Payment From Merck KGaA for Positive Results From Phase 2 Trial of TH-302 in Pancreatic Cancer | | 120 | MarketWire |
| SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/11/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced it has earned a $20 million milestone payment from Merck KGaA, Darmstadt, Germany...
Mehr lesen zu:
Threshold Pharmaceuticals Earns $20 Million Milestone Payment From Merck KGaA for Positive Results From Phase 2 Trial of TH-302 in Pancreatic Cancer | |
| 30.03.
| Threshold Pharmaceuticals (THLD) Reports Positive Phase 2b Trial of TH-302 in Pancreatic Cancer | | 1 | StreetInsider.com |
| 30.03.
| Threshold Pharmaceuticals Announces Detailed Results From Positive Phase 2b Trial of TH-302 in Pancreatic Cancer at AACR Annual Meeting | | 101 | MarketWire |
| SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/30/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)
Primary progression-free survival efficacy endpoint met (p=0.005)
Response rate of 27%...
Mehr lesen zu:
Threshold Pharmaceuticals Announces Detailed Results From Positive Phase 2b Trial of TH-302 in Pancreatic Cancer at AACR Annual Meeting | |
| 30.03.
| Threshold Pharmaceuticals Receives US Orphan Drug Designation for TH-302 for the Treatment of Soft Tissue Sarcoma | | 54 | MarketWire |
| SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/30/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the US Food and Drug Administration (FDA) has granted Orphan Drug Designation...
Mehr lesen zu:
Threshold Pharmaceuticals Receives US Orphan Drug Designation for TH-302 for the Treatment of Soft Tissue Sarcoma | |
| 28.03.
| Threshold Pharmaceuticals Announces Multiple Data Presentations on TH-302 at the 2012 AACR Annual Meeting / Oral, Late-Breaking Presentation and Subsequent Webcast to Detail Efficacy and Safety Data From Phase 2b Trial of TH-302 in Pancreatic Cancer | | 29 | MarketWire |
| SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/28/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that TH-302 will be featured in four presentations, including a late-breaking...
Mehr lesen zu:
Threshold Pharmaceuticals Announces Multiple Data Presentations on TH-302 at the 2012 AACR Annual Meeting / Oral, Late-Breaking Presentation and Subsequent Webcast to Detail Efficacy and Safety Data From Phase 2b Trial of TH-302 in Pancreatic Cancer | |
| 16.03.
| Threshold Pharma (THLD) Gets EC Orphan Drug Designation for TH-302 | | 1 | StreetInsider.com |
| 16.03.
| Threshold Pharmaceuticals' TH-302 Receives Orphan Drug Designation in the European Union for the Treatment of Soft Tissue Sarcoma | | 79 | MarketWire |
| SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/16/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the European Commission has granted Orphan Drug Designation for TH-302, a hypoxia-targeted...
Mehr lesen zu:
Threshold Pharmaceuticals' TH-302 Receives Orphan Drug Designation in the European Union for the Treatment of Soft Tissue Sarcoma | |
| 14.03.
| Threshold Pharma (ThLD) Doses First Patient in TH-302 Phase 1/2 | | 3 | StreetInsider.com |
| 14.03.
| Threshold Pharmaceuticals Doses First Patient in Clinical Trial Evaluating TH-302 in Multiple Myeloma | | 44 | MarketWire |
| SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/14/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the first patient has been dosed in its Phase 1/2 clinical trial of TH-302...
Mehr lesen zu:
Threshold Pharmaceuticals Doses First Patient in Clinical Trial Evaluating TH-302 in Multiple Myeloma | |
| 12.03.
| Threshold Pharmaceuticals' TH-302 to Be Featured at Symposium on Hypoxia in Cancer Hosted by the New York Academy of Sciences | | 35 | MarketWire |
| SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/12/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) announced that TH-302 will be featured among several presentations by academic and industry experts...
Mehr lesen zu:
Threshold Pharmaceuticals' TH-302 to Be Featured at Symposium on Hypoxia in Cancer Hosted by the New York Academy of Sciences | |
| 08.03.
| Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial and Operational Results | | 78 | MarketWire |
| SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/08/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2011. The...
Mehr lesen zu:
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial and Operational Results | |
| 06.03.
| Threshold Pharmaceuticals Announces Oral Presentation on TH-302 Clinical Study at the 2012 AACR Annual Meeting | | 47 | MarketWire |
| SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/06/12 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that a Late-Breaking clinical abstract has been selected for presentation at the...
Mehr lesen zu:
Threshold Pharmaceuticals Announces Oral Presentation on TH-302 Clinical Study at the 2012 AACR Annual Meeting | |
